Participating Companies

Alligator Bioscience [ATORX:ST] SKr944 MM MCap
The com­pany spe­cial­izes in the de­vel­op­ment of tu­mor-di­rect­ed im­munother­a­pies, in par­tic­u­lar ag­on­is­tic mono- and bis­pe­cif­ic anti­bodies. In im­munother­a­py, the pa­tients´ im­mune sys­tem is ac­ti­vat­ed to cure can­cer. The term tu­mor-di­rect­ed means that the drug is ad­min­is­tered or de­signed such that the phar­ma­co­log­i­cal ef­fect is lo­cal­ized to the tu­mor. [more in­for­ma­tion]
Bone Therapeutics SA [BT1:FF] €38 MM MCap
Bone Ther­a­peu­tics is a biotech­nol­o­gy com­pany with a unique ap­proach to the de­vel­op­ment of cell ther­a­py prod­ucts for bone frac­ture re­pair and frac­ture pre­ven­tion. Bone Ther­a­peu­tics' tech­nol­o­gy is based on a unique, pro­pri­e­tary ap­proach to bone re­gen­er­a­tion which turns un­d­if­fer­en­ti­at­ed stem cells in­to “os­teoblas­tic”, or bone-form­ing cells. [more in­for­ma­tion]
Carisma Therapeutics Inc.
Pi­oneer­ing the de­vel­op­ment of CAR macrophages, a dis­rup­tive ap­proach to im­munother­a­py. The tech­nol­o­gy lev­er­ages ad­vances in macrophage bi­ol­o­gy, chimer­ic anti­gen re­cep­tor en­gi­neer­ing and adop­tive cel­lu­lar ther­a­py for the treat­ment of hu­man dis­ease. [more in­for­ma­tion]
CureVac AG
Cure­vac is a pri­vate Ger­man com­pany with mR­NA plat­form, di­ver­si­fied pipe­line, and three lead pro­grams in ph1: CV8102 (vari­ous can­cer in­di­ca­tions), CV9202 (NS­CLC) and CV7202 (Ra­bies). Last fi­nanc­ing round done at over $1bn. Other com­pa­nies in the space: MR­NA, TBIO, BN­TX. [more in­for­ma­tion]
Hookipa Pharma [HOOK] US$187 MM MCap
is a clin­i­cal stage com­pany de­vel­op­ing prod­ucts to pre­vent and cure in­fec­tious dis­eas­es and can­cer. With this goal in mind we cre­at­ed unique and cutt­ing-edge tech­nolo­gies which re­pro­gram and sti­m­u­late the im­mune sys­tem. We are build­ing a pro­pri­e­tary im­mune-on­col­o­gy pipe­line by tar­get­ing Ther­aT® to­wards HPV+ head and neck squa­mous cell car­ci­no­ma and pros­tate can­cer. [more in­for­ma­tion]
The com­pany raised $9 mil­lion of grant fund­ing from Bill & Melin­da Gates Foun­da­tion on Jan­uary 9, 2017. The com­pany will use the fund­ing to strengthen its work to de­vel­op treat­ments and vaccines for in­fec­tious dis­ease us­ing its anti­body plat­form. [more in­for­ma­tion]
Mabion SA [0QGW.L]
The Com­pany’s pro­ject of the most pri­or­i­ty is the in­tro­duc­tion to mar­ket the Mabion­CD20 drug, biosim­i­lar medicine to MabThera (Ri­t­ux­imab). The ther­a­peu­tic in­di­ca­tions for the drug are for Non-Hodgkin’s lym­pho­ma, Leukemia and Rheu­ma­toid Arthri­tis (RA). [more in­for­ma­tion]
Medivir AB [MVIR B:ST] SKr936 MM MCap
Biri­na­pant/Keytru­da® com­bo in Ph 2 MSS CRC with in­ter­im da­ta in 4Q19; MIV-818 in Ph 1 in liv­er can­cer, ear­ly POC Ph 1a da­ta in 2Q19 / Phase 1b to start in 4Q19. Remeti­no­s­tat in Ph 2 ISS study for BCC, pos­i­tive in­ter­im da­ta in 2Q19. BD/li­cenc­ing op­por­tu­ni­ties: Ph 3 ready MIV-711 for OA and Ph 3 ready remeti­no­s­tat for CT­CL. [more in­for­ma­tion]
Nanobiotix SA [NANO:PA] €160 MM MCap
Nano­bi­otix is a lead­ing, clin­i­cal-stage nanomedicine com­pany pi­oneer­ing new ap­proach­es to sig­ni­f­i­cant­ly change pa­tient out­comes by bring­ing nano­physics to the heart of the cell. Nano­bi­otix’s Im­muno-On­col­o­gy pro­gram has the po­ten­tial to bring a new di­men­sion to can­cer im­munother­a­pies. [more in­for­ma­tion]
The Com­pany re­port­ed Phase 2 ef­fi­ca­cy and safe­ty da­ta for NRX-011 in De­cem­ber 2018, suggest­ing po­ten­tial for NRX-101 in main­tain­ing re­mis­sion from sev­er­al bipo­lar de­pres­sion with acute sui­ci­dal idea­tion fol­low­ing an ini­tial sta­bi­l­iza­tion with ke­tamine. [more in­for­ma­tion]
Nicox [COX:PA] €133 MM MCap
An in­ter­na­tio­n­al oph­thalmic R&D com­pany, aim­ing to build a di­ver­si­fied port­fo­lio of ther­a­peu­tic prod­ucts ad­dress­ing the needs of eye­care prac­ti­tion­ers and pa­tients around the world. [more in­for­ma­tion]
Oryzon Genomics [ORY:MA]
Tar­get­ing ly­sine spe­cif­ic demethy­lase 1 (LS­D1, aka KD­M1A). Lead CNS com­pound in 3 Phase 2a trials in MS, AD and bas­ket trial. Onc com­pound in 2 com­bo Phase 2a trials in AML and SCLC. Da­ta exp mid-2019 [more in­for­ma­tion]
Remi­ma­zo­lam: short-act­ing anes­thet­ic. Ph 3 study in pro­ce­du­ral se­da­tion in US. Safe­ty da­ta in ASA III/IV pa­tients in Ph 3 colonos­copy study and Ph 3 bron­chos­copy study. US ap­pro­val filed by part­n­er Cos­mo Phar­ma­ceu­ti­cals in June 2019. Ini­ti­at­ed Ph 3 in gen­er­al anes­th­e­sia in EU in Ju­ly 2018, exp com­ple­tion 2019. [more in­for­ma­tion]
Pharming Group NV [PHARM:AS] €764 MM MCap
De­vel­op­ment pipe­line in­cludes RU­CON­EST in new ver­sions (LCM), new li­cense from No­var­tis of late stage drug Le­ni­olis­ib for APDS (ul­tra-rare im­mun­od­e­fi­cien­cy con­di­tion), rhC1INH for new larg­er in­di­ca­tions in­clud­ing con­tract-in­duced nephro­pa­thy, pre-eclamp­sia and AKI, re­com­bi­nant al­pha-Glu­cosi­dase for Pompe dis­ease [more in­for­ma­tion]
Poxel SA [POXEL:PA] €192 MM MCap
Imeglimin (mi­to­chon­dria-based MOA) for T2D be­gan Ph 3 in Ja­pan with Asian part­n­er Su­m­i­t­o­mo Dainip­pon. Com­ple­tion of Phase 3 on track for 2019 and JN­DA sub­mis­sion in 2020. In 1Q18, an­nounced agree­ment w Roi­vant for Imeglimin (Ph 3 ready) in US, EU, and ad­dl coun­tries WW. [more in­for­ma­tion]
PsiOxus Therapeutics
The ther­a­py (NG-348), us­es virus to tran­s­port two ther­a­peu­tic genes di­rect­ly in­to tu­mors to re­cruit im­mune cells in­to at­tack­ing tar­get­ed can­cer cells. Up­com­ing Mile­s­tones: - 2 pro­grams in clin­ic with read­outs in 2019 (ovarian can­cer in comb w Pa­cl­i­tax­el, car­ci­no­mas in comb w nivolumab) - 2 INDs in 2018 (NG-348 and NG-350A) - 2 INDs in 2019 (NG-641 and NG-347) [more in­for­ma­tion]
San­i­fit is a bio­phar­ma­ceu­ti­cal com­pany fo­cused on treat­ments for cal­ci­fi­ca­tion di­s­or­ders, with SN­F472 as the lead com­pound. The com­pany is plan­n­ing to ini­ti­ate a phase III study in this or­phan dis­ease in 2018. The on­go­ing phase IIb study (Calip­so) in ES­RD pa­tients on dial­y­sis is eval­u­at­ing the ef­fect of SN­F472 on pro­gres­sion of ar­te­rial cal­ci­fi­ca­tion. [more in­for­ma­tion]
Targovax [TRVX:OS] NKr335 MM MCap
Strong re­sults from Part 1 (ON­COS-102/Keytru­da com­bo) trial in an­ti-PD1 re­frac­to­ry me­lano­ma: 33% ORR in 9 pts: 1 CR, 2 PRs; in all 9 pts. Up­com­ing mile­s­tones: ran­domized da­ta, Ph 1b/2 (me­sothe­lio­ma, n=31) w/che­mo: Jan 2020; Ph 1, Part 2 da­ta (me­lano­ma comb w/Keytru­da, n=21): 1H2020; up­dates from col­lab part­n­ers in peri­toneal me­tas­ta­sis & pros­tate exp 2020 [more in­for­ma­tion]